NCT04466098View on ClinicalTrials.gov

Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

July 30, 2020

Primary Completion Date

February 25, 2022

Study Completion Date

December 31, 2024

Conditions
Acute Respiratory Distress SyndromeARDS (Moderate or Severe)COVID-19 Pneumonia
Interventions
BIOLOGICAL

Mesenchymal stromal cells

Thawed product containing MSC(300x10\^6) in DMSO resuspended 1:1 with Dextran 40 + 5% human serum albumin \[total volume 60 mL\]

OTHER

Placebo

Dextran 40 + 5% human serum albumin \[total volume 60 mL\]

Trial Locations (2)

15261

University of Pittsburgh, Pittsburgh

55455

University of Minnesota, Minneapolis

All Listed Sponsors
lead

Masonic Cancer Center, University of Minnesota

OTHER

NCT04466098 - Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19) | Biotech Hunter | Biotech Hunter